Klinische Studie über die Sicherheit und die Wirksamkeit des Medikaments BAY2433334 bei Patienten mit Vorhofflimmern

Drug: BAY2433334;Drug: Apixaban;Other: BAY2433334 matching placebo;Other: Apixaban matching placebo

Inclusion Criteria:

- Participant must be 45 years of age or older at the time of signing the informed
consent.

- Participant with AF documented by ECG evidence with

- CHA2DS2-VASc score = 2 if male or CHA2DS2-VASc score = 3 if female

- Indication for treatment with an oral anticoagulant in

- any participant currently not treated with an oral anticoagulant (e.g.
treatment naïve) or alternatively,

- participant on a NOAC in case of at least one bleeding risk feature (history
of a prior bleed within the last 12 months requiring medical attention and /
or moderate renal dysfunction with eGFR 30-50 ml/min and / or current
clinically indicated antiplatelet therapy with Acetylsalicylic acid(ASA) =
100 mg)

- Written informed consent

Exclusion Criteria:

- Mechanical heart valve prosthesis

- Any degree of rheumatic mitral stenosis or moderate-to-severe, non-rheumatic mitral
stenosis

- Atrial fibrillation due to a reversible cause, participants in sinus rhythm after
successful ablation, or plan for cardioversion or ablation during study conduct

- Requirement for chronic anticoagulation (for a different indication than AF) or
antiplatelet therapy (up to 100 mg ASA is allowed). Anticipated need for chronic
therapy with Nonsteroidal anti-inflammatory drugs (NSAIDs)

- Treated with a Vitamin K antagonist in the 30 days prior to screening